TREATMENT OF EXPERIMENTAL INTRACRANIAL MURINE MELANOMA WITH A NEUROATTENUATED HERPES-SIMPLEX VIRUS-1 MUTANT

被引：100

作者：

RANDAZZO, BP

KESARI, S

GESSER, RM

ALSOP, D

FORD, JC

BROWN, SM

MACLEAN, A

FRASER, NW

机构：

[1] WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA

[2] UNIV PENN, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA

[3] UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA

[4] UNIV PENN, DEPT RADIOL, PHILADELPHIA, PA 19104 USA

[5] CHILDRENS HOSP, DIV ALLERGY IMMUNOL & INFECT DIS, PHILADELPHIA, PA 19104 USA

[6] MRC, INST VIROL, GLASGOW, LANARK, SCOTLAND

来源：

VIROLOGY | 1995年 / 211卷 / 01期

关键词：

D O I：

10.1006/viro.1995.1382

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Brain metastases occur commonly in the setting of a variety of human cancers. At present, such cases are invariably fatal and highlight a need for research on new therapies. We have developed a mouse brain tumor model utilizing the Harding-Passey melanoma cell line injected intracranially into C57Bl/6 mice. Tumors develop in 100% of the mice and can be detected by magnetic resonance imaging as early as 5 days post cell injection. Death from tumor progression occurs between 12 and 16 days post cell injection. stereotactic injection of the neuroattenuated HSV-1 strain 1716 into brain tumors 5 or 10 days postinjection of the melanoma cells results in a statistically significant increase in the time to development of neurological symptoms and in complete tumor regression and the long-term survival of some treated animals. Moreover, viral titration studies and immunohistochemistry suggest that replication of this virus is restricted to tumor cells and does not occur in the surrounding brain tissue. These results suggest that HSV-1 mutant 1716 shows particular promise for use as a therapeutic agent for the treatment of brain tumors. (C) 1995 Academic Press, Inc.

引用

页码：94 / 101

页数：8

共 39 条

[1]

Ace C.I., McKee T.A., Ryan J.M., Cameron J.M., Preston C.M., Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate early gene expression, J. Virol, 63, pp. 2260-2269, (1989)

[2]

Ackermann M., Longnecker Roizman R.B., Pereira L., Identification, properties, and gene location of a novel glycoprotein specified by herpes simplex virus, J Virology, 150, pp. 207-220, (1986)

[3]

Amer M.H., Al-Sarraf M., Baker L.H., Vaitkevicius V.K., Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival, Cancer, 42, pp. 660-668, (1978)

[4]

Balch C.M., Soong S.-J., Murad T.M., Smith J.W., Maddox W.A., Durant J.R., A multifactoriaI analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III), J. Clin. Oncol, 1, pp. 126-132, (1983)

[5]

Bleehen S.S., Ultra structural studies on tumors and cell cultures of the Harding-Passey mouse melanoma, Br. J. Dermatol, 90, (1974)

[6]

Bolovan C.A., Sawtell N.M., Thompson R.L., ICP 34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures, J. Virol, 68, pp. 48-55, (1994)

[7]

Budman D.R., Camacho E., Wittes R.E., The current causes of death in patients with malignant melanoma, Eur. J, Cancer, 14, pp. 327-330, (1978)

[8]

Castillo R., Diaz J.W., Veloso A., Gavilondo J., Leukemoid reaction induced by different transplantable tumors in three inbred mouse strains, Neoplasma, 29, pp. 73-79, (1982)

[9]

Chou J., Kern E.R., Whitley R.J., Roizman B., Mapping of herpes simplex virus neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture, Science, 250, pp. 1262-1266, (1990)

[10]

Coen D.M., Fleming H.E., Leslie L.K., Retondo M.J., Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus, J. Virol, 53, pp. 477-488, (1985)

← 1 2 3 4 →